When Gilead acquired CAR-T leader Kite Pharma, it made a crucial decision not to fully integrate it. This preserved Kite's distinct, individualized therapy operating model, which is fundamentally different from a traditional "off-the-shelf" drug company, proving a key lesson in M&A strategy for novel platforms.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

Gilead is betting it can overcome the manufacturing and supply chain challenges that have limited J&J's successful Carvykti therapy. While Arcellx's AnitoCell shows similar efficacy, justifying the premium price tag depends on delivering a more reliable and scalable manufacturing process, which remains unproven.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

AbbVie's deal for ZG006, a Phase 3 T-cell engager, shows the premium on late-stage oncology assets. The $100 million upfront payment for rights outside China, plus significant milestones, underscores a strategy to in-license de-risked candidates to quickly bolster pipelines in competitive areas like small cell lung cancer.

Go beyond standard performance-based earn-outs by structuring payments with 'kickers' that reward sellers for specific de-risking actions. For example, if there's high customer concentration, offer an additional payment for diversifying revenue away from the main client, aligning them with the buyer's risk mitigation goals.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

In its acquisition of Bluejay, Mirum employed a creative deal structure combining stock and cash. The stock component ensures Bluejay's shareholders remain invested in the asset's success, while sales milestones de-risk the acquisition for Mirum and allow the selling team to share in future upside, creating a win-win partnership.

Neurix's deals with Sanofi and Gilead involve the partner funding early development through human proof-of-concept, minimizing Neurix's upfront financial risk. Crucially, the deal structure allows Neurix to "opt-in" for a 50/50 profit share in the U.S. later, retaining significant upside on successful programs.